Engineered Deoxyribose-Phosphate Aldolases for Chiral Nucleoside Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for more effective compounds that inhibit HIV reverse transcriptase to ameliorate the effects of AIDS, as existing compounds like azidothymidine are not sufficiently potent.
Innovation Solution
Engineered deoxyribose-phosphate aldolases with specific polypeptide sequences are developed to catalyze the conversion of enantiopure (R)-2-ethynyl-glyceraldehyde into (4S,5R)-5-ethynyl-deoxyribose, which can be further processed to produce nucleoside reverse transcriptase translocation inhibitors (NRTTIs) for HIV treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemical synthesis is used to produce nucleoside reverse transcriptase translocation inhibitors, then the production process is well-established, but the effectiveness of the resulting compounds in inhibiting HIV reverse transcriptase is insufficient
Solution Approach 1:
The patent replaces traditional chemical synthesis methods with a biocatalytic system using engineered deoxyribose-phosphate aldolase enzymes. This substitution enables the production of nucleoside reverse transcriptase translocation inhibitors with improved effectiveness while maintaining manufacturability through enzymatic catalysis rather than complex chemical reactions
Solution Approach 2:
The patent employs protein engineering techniques to modify the amino acid sequence of deoxyribose-phosphate aldolase enzymes, creating variants with enhanced catalytic properties. By changing parameters such as enzyme specificity, activity, and stability through amino acid substitutions, the biocatalytic process produces compounds with superior HIV reverse transcriptase inhibition effectiveness
2Reliability
If existing reverse transcriptase inhibitors like azidothymidine are used, then the treatment approach is simple and well-established, but the potency against HIV reverse transcriptase is not sufficient
Solution Approach 1:
The patent divides the synthesis process into distinct biocatalytic steps performed by engineered enzyme variants. The deoxyribose-phosphate aldolase enzymes catalyze specific aldol reactions to build complex nucleoside structures with built-in chirality, segmenting the overall synthesis into manageable enzymatic steps that produce high-potency compounds
Solution Approach 2:
The engineered deoxyribose-phosphate aldolase enzymes serve as intermediaries that transform simple substrates into complex nucleoside intermediates with specific stereochemistry. These enzyme intermediaries enable the production of potent HIV reverse transcriptase translocation inhibitors that cannot be easily obtained through conventional chemical synthesis
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered aldolases provide a biocatalytic route for producing pharmaceutical compounds that are more effective in inhibiting HIV reverse transcriptase, offering a promising alternative to traditional chemical synthesis.
Implementation Method 1
deoxyribose-phosphate aldolases comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NOS: 2, 6, and/or 466... wherein the engineered deoxyribose-phosphate aldolase comprises at least one substitution or substitution set in the polypeptide sequence
Implementation Method 2
engineered deoxyribose-phosphate aldolases useful under industrial process conditions for the production of pharmaceutical and fine chemical compounds
Data Source
AI summary
The present invention provides engineered deoxyribose-phosphate aldolase polypeptides useful under industrial process conditions for the production of pharmaceutical and fine chemical compounds.